Aummune

Aummune Overview

Aummune is a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Its proprietary platform utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional oligonucleotide drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses. Aummune’s lead program, AM003, has already initiated its Phase 1 clinical trial following successful demonstrations of efficacy and safety in multiple animal models. The company is now actively recruiting patients for this First-in-Human study, which targets those with locally advanced and metastatic solid tumors.

Cumulative Funding Raised Over Time ($)

Latest News

No news articles.

Funding

Team Members

4

Employees: 1-10

Web & Social Links

Locations

Weizmann St 6, Tel Aviv-Yafo, Israel

Photos & Videos

No files yet

Aummune Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info